Rabbit Polyclonal GALE Antibody

The GALE antibody targets UDP-galactose-4-epimerase (GALE), a critical enzyme in the Leloir pathway responsible for galactose metabolism. GALE catalyzes the interconversion of UDP-galactose and UDP-glucose, essential for maintaining cellular glycosylation and energy homeostasis. Mutations in the GALE gene are linked to galactosemia type III, a rare metabolic disorder characterized by impaired galactose processing, leading to complications like liver dysfunction, developmental delays, and cataracts. Research on GALE antibodies has been pivotal in studying enzyme expression, localization, and dysfunction in disease models. These antibodies are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to assess GALE protein levels in tissues or cell lines, aiding in diagnosing genetic variants and understanding molecular mechanisms underlying galactosemia. Recent studies also explore GALE's role beyond galactosemia, including its potential involvement in cancer progression and glycobiology. Monoclonal and polyclonal GALE antibodies are commercially available, with validation for specificity and sensitivity across species. Ongoing work focuses on refining antibody-based assays to support therapeutic development, such as enzyme replacement therapies or small-molecule correctors for GALE-deficient conditions.